Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose
Minchom, A. R. Krebs, Matthew G Cho, B. C. Lee, S. H. Leighl, N. B. O'Neil, B. Sabari, J. K. Kudgus-Lokken, R. Alhadab, A. Haddish-Berhane, N.
Minchom, A. R.
Krebs, Matthew G
Cho, B. C.
Lee, S. H.
Leighl, N. B.
O'Neil, B.
Sabari, J. K.
Kudgus-Lokken, R.
Alhadab, A.
Haddish-Berhane, N.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Minchom AR, Krebs MG, Cho BC, Lee SH, Leighl NB, O'Neil B, et al. Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003793.